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Apolipoprotein E4 and Insulin 
Resistance Interact to Impair 
Cognition and Alter the Epigenome 
and Metabolome
Lance A. Johnson1,†, Eileen Ruth S. Torres1, Soren Impey2,3, Jan F. Stevens4,5 & Jacob Raber1,6
Apolipoprotein E4 (E4) and type 2 diabetes are major risk factors for cognitive decline and late onset 
Alzheimer’s disease (AD). E4-associated phenotypes and insulin resistance (IR) share several features 
and appear to interact in driving cognitive dysfunction. However, shared mechanisms that could explain 
their overlapping pathophysiology have yet to be found. We hypothesized that, compared to E3 mice, 
E4 mice would be more susceptible to the harmful cognitive effects of high fat diet (HFD)-induced 
IR due to apoE isoform-specific differences in brain metabolism. While both E3 and E4 mice fed HFD 
displayed impairments in peripheral metabolism and cognition, deficits in hippocampal-dependent 
spatial learning and memory were exaggerated in E4 mice. Combining genome-wide measures of DNA 
hydroxymethylation with comprehensive untargeted metabolomics, we identified novel alterations in 
purine metabolism, glutamate metabolism, and the pentose phosphate pathway. Finally, in E4 mice, 
the metabolic and cognitive deficiencies caused by HFD were rescued by switching to a low fat diet for 
one month, suggesting a functional role was associated with reversal of the same metabolic pathways 
described above. These results suggest a susceptibility of E4 carriers to metabolic impairments brought 
on by IR, and may guide development of novel therapies for cognitive decline and dementia.
Apolipoprotein E4 (E4) and type 2 diabetes (T2D) share pathophysiological features that are linked to cognitive 
impairment and dementia. However, it is unclear if these two critical risk factors interact to worsen cognitive 
decline, and the shared mechanisms that could explain their overlapping pathology have yet to be found.
The most significant genetic risk factor for late onset Alzheimer’s disease (AD) is E41. The APOE gene encodes 
three major isoforms in the human population (E2, E3, and E4)2. In the periphery, apoE is associated with circu-
lating lipoproteins, primarily very low density lipoproteins (VLDL) and high density lipoproteins (HDL), while 
the brain synthesizes its own pool of apoE, the majority of which are secreted by astrocytes3. In addition to 
well-established effects on AD pathology, apoE also shows substantial isoform-specific effects on metabolism4.
Obesity and diabetes have reached epidemic proportions worldwide5. Aside from traditional complications, 
obesity, insulin resistance (IR) and T2D pose additional health risks in the form of cognitive dysfunction and 
dementia. Compared with non-diabetic individuals, those with diabetes have a ∼ 70% greater risk for the devel-
opment of vascular dementia or AD6. Obesity and IR are also associated with decreased cognitive function and 
an increased risk of dementia, even in the absence of overt diabetes7. Finally, AD itself is associated with increased 
incidence of diabetes8, and the brains of patients with mild cognitive impairment (MCI) and AD are functionally 
insulin resistant9.
E4 and T2D also appear to act synergistically to drive cognitive dysfunction and increase the risk of AD 
and vascular dementia10,11. E4 and T2D share characteristics with established links to neurodegeneration. For 
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instance, while glucose hypometabolism is a core feature of AD, E4 itself has also been associated with lower 
rates of cerebral glucose metabolism12. Several other pathways that are negatively influenced by brain insulin 
levels are similarly altered in E4 + individuals, including amyloid β clearance, neuroinflammation, and synaptic 
dysfunction3,13.
A primary, modifiable contributor to obesity, IR and T2D is caloric excess, particularly in the form of high 
intake of saturated fats and high glycemic index foods. Consumption of this Western style diet increases the risk 
of dementia, and the effects may be modulated by APOE genotype14. However, examining the interaction between 
E4 and diet in humans is difficult due to considerable individual variations in dietary habits and differences in 
genetic factors other than APOE. Therefore, we employed a mouse model of human apoE to study the interaction 
of E4 with high fat diet (HFD)-induced IR on brain metabolism and cognitive function, and to identify potential 
pathways driving this interaction. Through the integration of genome-wide measures of epigenetic changes and 
untargeted metabolomics, we highlight several novel and interconnected metabolic pathways that may underlie 
the observed cognitive impairments.
Results
HFD results in glucose intolerance in E3 and E4 mice; reduced weight gain in E4 mice. After 
six months of HFD or LFD, we measured markers of peripheral metabolism, evaluated cognitive function, and 
analyzed the hippocampal epigenome and metabolome in human apoE mice (Fig. 1A). HFD led to increases 
in body weight and adipose tissue mass in both groups. However, E4 mice gained less weight and less visceral 
adipose tissue than E3 mice (Fig. 1B–C). Higher measures of glucose intolerance have previously been negatively 
associated with cognitive function in humans15, and this relationship may be modified by apoE isoform14,16,17. 
However, fasting glucose and insulin levels were similarly elevated in E3 HFD and E4 HFD mice (Fig. 1D–E), and 
both E3 HFD and E4 HFD mice showed delayed glucose clearance following an oral challenge compared to LFD 
controls (Fig. 1F).
HFD-induced impairments in spatial learning and memory, but not in object recognition or 
cued fear memory, are exaggerated in E4 mice. To assess cognitive function, we first examined object 
recognition (Fig. 1G–H). When introduced to a ‘familiar’ and a ‘novel’ object, E3 LFD and E4 LFD mice showed a 
robust preference for the novel object but neither E3 HFD nor E4 HFD mice did, indicating impaired recognition 
memory (Fig. 1G–H). We next assessed cued fear learning and memory. All groups showed similar acquisition of 
fear, shock response, and baseline motion during training (Figure S1A–C). However, both E3 HFD and E4 HFD 
mice showed decreased freezing when reintroduced to the tone 24 hours later (Fig. 1I), indicating impaired cued 
fear memory.
We next assessed spatial learning and memory in the water maze. Despite similar swim speeds (Figure S1D), 
HFD mice required more time to reach a clearly marked platform than LFD mice (Fig. 1J, visible), indicating 
difficulties in general task learning. When the platform was hidden from view, E4 HFD mice showed significantly 
worse learning curves compared to E4 LFD and E3 HFD mice (Fig. 1J, hidden). To test long-term memory reten-
tion, we conducted probe trials (no platform) at 24 (Figure S1E–F) and 72 (Fig. 1K) hours post-training. E3 HFD 
and E4 HFD mice showed impaired spatial memory retention in both probe trials. While E3 HFD mice showed 
spatial memory retention following additional training, E4 HFD mice did not (Fig. 1K). Representative heat maps 
tracking search strategies, as well as the time to first cross the platform location, also showed clear deficits in E4 
HFD mice (Fig. 1L–M). Thus, HFD-induced deficits in hippocampus-dependent spatial learning and memory are 
more pronounced in mice expressing E4 than E3.
These cognitive deficits appeared specific to HFD-induced IR, as despite severe hyperglycemia (> 400 mg/dl 
fasting glucose), there were no significant cognitive impairments in either E3 or E4 mice in a separate cohort of 
mice with type 1 diabetes (T1D) (Figure S2).
E4 HFD mice show a unique profile of DNA hydroxymethylation in the hippocampus. 
Alterations in DNA methylation may contribute to the pathogenesis of T2D and its complications18. 
5′-hydroxymethylated DNA (5hmC) appears especially important for cognitive processes, and changes in 5hmC 
strongly correlate with transcriptionally active regions19,20. Because the E4-exaggerated cognitive deficits were 
hippocampus-dependent, we performed an unbiased, genome-wide analysis of 5hmC in the hippocampus of E3 
and E4 mice. The global distribution of epigenetic marks was similar among groups, as accumulation of 5hmC in 
intragenic, intergenic, exonic, and untranslated regions did not significantly differ (Figure S3A). Although global 
distributions of 5hmC signal were not altered, thousands of differentially hydroxymethylated regions (DHR) 
were significantly affected by apoE isoform and/or diet. The most dramatic changes in 5hmC levels were observed 
between comparisons of E4 HFD vs E4 LFD (4,782 total DHRs) or E3 HFD mice (4,753 total DHRs) (Fig. 2A–B). 
Furthermore, a large number of the DHRs were unique to E4 HFD mice. For example, more than half of the 
DHRs in E4 HFD mice were uniquely hypomethylated compared to E3 HFD mice (1,627/2,381), or hypermeth-
ylated compared to E4 LFD mice (2,361/4,138) (Fig. 2B, bold).
To identify putative biological functions for the DHRs, we performed gene ontology (GO) analyses. Our 
analyses revealed numerous cellular component GO categories specific to neurons, including synapse and neu-
ron projection (Fig. 2C). The most substantial changes, both in significance and number of pathways affected, 
were seen in E4 HFD mice. They included terms related to neuron differentiation, axonogenesis, intracellular 
signaling, nucleic acid regulation, and phosphate metabolism (Figure S3B). We next compared DHRs using a 
KEGG pathway-based GO analysis. Again, the most significant changes occurred in E4 HFD mice, and involved 
pathways related to neuronal function, vascular physiology, cell adhesion, proteoglycan synthesis, and signa-
ling (Fig. 2D). Additionally, several genes known to co-regulate multiple pathways listed above were uniquely 
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hydroxymethylated in E4 HFD mice (Figure S3C). Thus, compared to E3, E4 mice show an exaggerated response 
and a unique pattern of neuronal-associated changes in hippocampal 5hmC when challenged with a HFD.
GO analyses for DHRs within 10 kb of a transcriptional start site did not identify significant categories. 
Analyses using a 20 kb window identified the following significant categories (p < 0.001): E3 LFD vs E3 HFD 
downregulated – membrane, protein binding, and cytoplasm; E4 LFD vs E4 HFD downregulated – membrane, 
positive regulation of transcription, ion transport; E3 HFD vs E4 HFD downregulated – protein binding, nucleus, 
cytoplasm. This suggests that proximal DHRs are associated with general cellular and/or metabolic processes.
ApoE isoform-dependent changes in the hippocampal metabolome. Employing untargeted 
metabolomics, we next detected and relatively quantified 12,464 unique MS/MS features within the hippocam-
pus of E3 and E4 mice. When evaluated using a supervised principal components analysis, the overall profile 
of E4 mice was shifted from that of E3 mice, regardless of diet (Fig. 3A). The majority of significantly altered 
features were due to apoE isoform (Fig. 3B). Using mass, retention time and MS/MS spectra, we confirmed the 
identity of 138 unique metabolites (Table S1), of which 58 were significantly altered by apoE isoform and/or diet 
(Figure S4A). Heat maps showing hierarchical clustering of altered metabolites between E3 and E4 mice revealed 
Figure 1. HFD-induced metabolic and cognitive impairments in spatial memory more pronounced in E4 
than E3 mice. (A) Peripheral metabolism and cognitive function were assessed following six months of HFD or 
LFD. Genome wide DNA hydroxymethylation, untargeted metabolomics, and an integrated analysis of the two 
were performed on isolated hippocampal tissue. (B) E4 HFD mice gain less weight. (n = 12–19) (C) E4 HFD mice 
accumulate less visceral adipose tissue following 6 months of HFD. (n = 12–14). (D-E) Chronic HFD induces 
hyperglycemia and hyperinsulinemia. Blood glucose (D) and plasma insulin (E) were measured following an 
overnight fast. (C, n = 17–24; D, n = 8–14). (F) Glucose intolerance is exaggerated in E4 HFD mice. Mice were 
administered an oral gavage of glucose following a four hour fast, and area under the curve was calculated. 
(n = 10–14). (G-H) Object recognition, 24 hours after training, is impaired in E3 HFD and E4 HFD mice. 
Familiar = open bars, novel = checkered bars. Representative tracks are shown in G. (n = 10–14). (I) Cued fear 
memory, 24 hours after training, is impaired in HFD mice. (n = 10–14). (J) E4 worsens HFD-induced deficits in 
spatial learning and memory in the water maze. Latency to locate a visible (left) or hidden (right) escape platform 
during the water maze. (n = 10–14). (K-M) HFD-induced deficits in long-term spatial memory are more 
profound in E4 mice. Long-term spatial memory was measured as the percent time spent searching in the target 
quadrant in a 72 hour probe trial (K). Representative heat maps (platform location right bottom quadrant) show 
deficits in search strategies in E4 HFD mice (L). The average time at which the mice first cross the target location 
is longer in E4 HFD mice (M). (n = 10–14) *p < 0.05, **p < 0.01 compared to E3; #p < 0.05, ##p < 0.01, compared 
to LFD (B, F, I, J, repeated measures ANOVA) (C-E, H, M, ANOVA followed by Tukey’s multiple comparison 
test). For K, *p < 0.05, **p < 0.01 Target quadrant compared to all other quadrants (ANOVA followed by Tukey’s 
multiple comparison test). T, target; R, right; L, left; O, opposite. Error bars represent mean ± SEM.
www.nature.com/scientificreports/
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distinct patterns of change (Fig. 3C,E). Among these metabolites, components of purine, various sugar (sucrose, 
galactose, fructose and mannose), and glycerophospholipid (GPL) pathways were most highly represented. While 
some overlap existed, a HFD altered distinct pathways in E3 and E4 mice: GPL and sphingolipid metabolism 
in mice with E3, and coenzyme A (CoA) biosynthesis and the pentose phosphate pathway (PPP) in mice with 
E4 (Figure S4B–E). Numerous pathways were altered in an apoE isoform-dependent fashion. In LFD mice, the 
pathways most significantly altered by apoE isoform were fructose, mannose and galactose metabolism, amino 
sugar and nucleotide sugar metabolism, glutamate metabolism, and the PPP (Fig. 3D). In HFD mice, the most 
significantly altered pathways included pantothenate and CoA biosynthesis, the PPP, GPL metabolism, starch and 
sucrose metabolism, and purine metabolism (Fig. 3F). In both LFD and HFD mice, the pathway most impacted 
by apoE isoform based on a measure of centrality was glutamate metabolism.
Integration of DNA hydroxymethylation and metabolomics analyses reveals alterations in 
three novel and interconnected metabolic pathways. DNA methylation and metabolism are tightly 
linked, with crosstalk at the molecular level21. To determine the overlap in pathways identified by the 5hmC and 
metabolomics analyses, we integrated the data using a platform that maps changes against established KEGG 
pathways. The resulting integrative analysis revealed multiple pathways that were significantly altered by both 
apoE isoform and HFD. They included changes related to glycerolipid metabolism and glycan biology (Fig. 4A). 
Of particular interest due to their biological relevance and interconnectivity are the PPP and the two pathways 
with the highest combined enrichment and topology scores: purine metabolism and glutamate metabolism 
(Fig. 4A–B). Within these three pathways, we identified multiple individual metabolites which were altered by 
apoE isoform and/or HFD. They included adenosine monophosphate (AMP), adenosine, and adenine within the 
purine metabolism pathway, gluconolactone, gluconate, and glucose 6-phosphate within the PPP, and glutamate 
(Fig. 4B).
Figure 2. E4 HFD mice show a unique profile of DNA hydroxymethylation in the hippocampus. (A) A 
large number of DHRs are hypermethylated in E4 HFD compared to E4 LFD mice. Histogram of differentially 
hypo-and hypermethylated regions for each comparison (FDR-adjusted -log[p < 0.05]). (For A-D, n = 10 
pools; 2 pools/experimental group, consisting of 4–6 individual DNA samples/pool). (B) Many DHRs are 
uniquely hypermethylated in E4 HFD mice. Venn diagrams depict directional overlap between differentially 
hydroxymethylated regions. Boxes show total number of DHRs for each comparison (FDR-adjusted 
-log[p < 0.05). Underlined numbers represent DHRs that were uniquely altered in E4 HFD mice. (C) Gene 
ontology shows enrichment in cell component categories specific to neurons. Bar graph depicts significantly 
enriched gene ontology terms in the indicated comparisons of DHRs based on a cellular component 
subset (number of significantly altered DHRs in each category are shown in italics). (D) Multiple pathways 
related to neuronal function, vascular physiology, cell adhesion, proteoglycan synthesis, and signaling are 
hypermethylated in E4 HFD mice. Categories represent the top 10 most significantly enriched gene ontology 
terms for the indicated comparisons of DHRs based on KEGG pathways. CS, chondroitin sulfate; HS, heparin 
sulfate; Neuroactive L-R inter. neuroactive ligand-receptor interaction; VSMC, vascular smooth muscle cell.
www.nature.com/scientificreports/
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A dietary intervention rescues HFD-induced impairments in E4 mice and reverses alterations 
in the hippocampal epigenome and metabolome. As E4 mice were particularly sensitive to the det-
rimental metabolic and cognitive effects of a HFD, we next asked whether these effects were reversible. An inde-
pendent group of E4 HFD mice were administered a LFD for one month following five months of HFD (hereafter 
referred to as E4 HFD → LFD) (Fig. 5A). Immediately following the switch to a LFD, E4 HFD → LFD mice lost 
substantial body weight and fat mass (Fig. 5B–C). The switch was associated with an improvement in glucose 
tolerance (Fig. 5D), and a complete rescue of cognitive function. E4 HFD → LFD mice showed robust object rec-
ognition (Fig. 5E), and despite similar learning curves and rates of generalized fear (Figure S5A–C), they showed 
enhanced freezing in response to a tone, suggesting a rescue of cued fear memory (Fig. 5F). E4 HFD → LFD 
mice also showed significant improvements in hippocampus-dependent spatial learning and memory (Fig. 5G), 
including long-term memory retention in the water maze (Figure S5E–H).
We next determined whether the observed rescue of cognitive function was associated with a reversal of 
HFD-induced changes in the hippocampal epigenome and metabolome. Multiple DHRs that were hypermethyl-
ated in E4 HFD vs E4 LFD mice were similarly altered in the E4 HFD vs E4 HFD → LFD comparison (Fig. 5H), 
indicating that many of the 5hmC changes associated with a HFD were reversed following the dietary interven-
tion. The Venn diagrams depict directional overlap between differentially hydroxymethylated regions. There was 
also substantial biological overlap in 5hmC patterns at the individual gene level (Table S2), as well as a majority 
of KEGG pathways differentially hydroxymethylated in E4 LFD mice being similarly altered in E4 HFD → LFD 
mice (Fig. 5I). Categories represent the top 10 most significantly enriched KEGG pathways for the comparison 
Figure 3. APOE genotype substantially alters the hippocampal metabolome. (A) Principal component 
analysis (PCA) score plot of the hippocampus metabolome shows distinct separation based on apoE isoform. 
(n = 8–9). (B) The majority of altered features differ by apoE isoform. The Venn diagram depicts overlap 
between significantly altered MS/MS features (p < 0.05 FDR adjusted). The box shows the total number of 
altered features for each comparison. (n = 8–9). (C–F) Multiple metabolic pathways are significantly altered 
in an apoE isoform-dependent fashion. Hierarchical clustering of the top 25 most significantly altered 
metabolites between E3 LFD and E4 LFD mice (C), or between E3 HFD and E4 HFD mice (E). Color in the 
heat map reflects the relative metabolite abundance level, with red being higher, and blue lower, than the mean 
value. Colored circles denote the metabolic pathway(s) in which each metabolite plays a role. A global view 
of the metabolome was created using a pathway impact analysis (D,F), which reflects key nodes in pathways 
that have been significantly altered in an apoE isoform-dependent fashion in LFD (D) or HFD (F) fed mice. 
The y-axis shows significance based on pathway enrichment, the x-axis shows impact based on a topology 
measure of centrality and connectedness, and circle size reflects the percentage of all metabolites within a 
given pathway that are represented. (n = 8–9). Abbreviations: 12-HETE, 12-Hydroxyeicosatetraenoic acid; 
AMP, Adenosine monophosphate; CoA, Coenzyme A; FADH, Flavin adenine dinucleotide (semiquinone); 
G6P, Glucose 6-phosphate; GDP, Guanosine diphosphate; GSSG, Glutathione disulfide; IMP, Inosine 
monophosphate; LPC, Lysophosphatidylcholine; NAGly, N-Arachidonoyl glycine; PA, Phosphatidic acid; PE, 
Phosphatidylethanolamine; PG, Phosphatidylglycerol.
www.nature.com/scientificreports/
6Scientific RepoRts | 7:43701 | DOI: 10.1038/srep43701
of DHRs between E4 HFD and E4 HFD → LFD mice (FDR-adjusted p < 0.05). Likewise, the most impacted met-
abolic pathways included the PPP, starch and sucrose metabolism, CoA biosynthesis, purine metabolism, and 
glutamate metabolism (Fig. 5J–K). Furthermore, multiple individual metabolites – the vast majority belonging 
to the aforementioned pathways – were significantly altered by the HFD → LFD intervention, with all returning 
to similar levels as E3 LFD controls (Fig. 5L). Finally, an integrated pathway analysis of the 5hmC and metabo-
lomics data showed that the HFD → LFD intervention affected, among others, the three previously highlighted 
pathways: purine metabolism, glutamate metabolism, and the PPP (Fig. 5M). The analysis integrates changes in 
metabolite concentrations with alterations in hydroxymethylation of genes associated with DHRs. Pathways in 
bold are significantly altered in both the E4 HFD vs E4 LFD and E4 HFD vs E4 HFD → LFD comparisons. These 
results point to a functional role for the aforementioned pathways, as they are significantly altered in an apoE 
isoform-dependent fashion by both HFD and the HFD → LFD dietary intervention.
Discussion
The pathologies of diabetes and dementia are strongly linked and both share features with the harmful processes 
associated with E4, the strongest genetic risk factor for late onset AD. However, the shared mechanisms that 
underlie this important connection have yet to be found. In the current study, we examined the effects of E4 on 
metabolism and cognitive function in a mouse model of HFD-induced IR using an unbiased and integrative 
approach for profiling metabolism within the hippocampus.
Figure 4. Integration of unbiased epigenetic and metabolomics analyses reveals alterations in several novel 
and interconnected metabolic pathways. (A) An integrated pathway analysis shows that multiple pathways are 
significantly altered by both apoE isoform and HFD. The analysis integrates changes in metabolite concentrations 
with alterations in DNA hydroxymethylation of genes associated with DHRs. The enrichment score evaluates 
whether the metabolites and genes in a particular pathway are overrepresented compared to random chance 
based on a hypergeometric analysis, while the topology score estimates the biological impact of a given gene 
or metabolite based on its position within a pathway. (For DNA hydroxymethylation, n = 10 pools; 2 pools/
experimental group, consisting of 4–6 individual DNA samples/pool; for metabolomics, n = 8–9). (B) Multiple 
metabolites related to purine metabolism, glutamate metabolism, and the pentose phosphate pathway are 
significantly altered by apoE isoform and/or HFD diet. Arrows note connected metabolites within each simplified 
metabolic pathway, while box and whisker plots show metabolite concentrations relative to E3 LFD.
www.nature.com/scientificreports/
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Figure 5. A dietary intervention rescues HFD-induced metabolic and cognitive impairments in E4 
mice and reverses epigenetic and metabolic changes. (A) A subset of E4 mice were fed HFD for 5 months, 
followed by LFD for one month (E4 HFD → LFD). (B-C) E4 HFD → LFD mice lose body weight and adipose 
tissue following the switch to a LFD. Body mass (B), and visceral fat (VF) and subcutaneous fat (SCF) pads 
(C) were weighed. (n = 9–19). (D) Glucose tolerance improves following the dietary intervention. Mice were 
administered an oral gavage of glucose following a 4 hour fast. (n = 9–13). (E) Object recognition is rescued in 
E4 HFD → LFD mice. (n = 7–12). (F) Cued fear memory is rescued in E4 HFD → LFD mice. (n = 7–12).  
(G) Spatial learning and memory in the water maze is rescued in E4 HFD → LFD mice. (n = 7–12). (H) Multiple 
www.nature.com/scientificreports/
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Interestingly, the cognitive impairments we observed in HFD fed E3 and E4 mice were not observed in a 
model of Type 1 Diabetes (T1D) – as we have previously observed in wildtype mice22 – suggesting that these 
negative cognitive effects are specific to the background of HFD-induced obesity and IR. However, many studies 
have demonstrated cognitive dysfunction in rodent models of T1D,23 and discrepancies with our results could be 
due to a number of factors including mouse age, sex and strain, the specific cognitive tasks employed, and deliv-
ery method of STZ (intracerebroventricular vs intraperitoneal vs intravenous). Still, our data are consistent with 
human studies where learning and memory are generally spared in T1D patients, while multiple memory deficits 
are noted even in the early stages of T2D24,25.
On the other hand, E4 and T2D share several neuropathological features3,13 including alterations in brain metab-
olism. Metabolic deficits are present decades in advance of AD onset. For instance, in the case of glucose hypome-
tabolism, reductions in cerebral glucose utilization are observed in normal E4 + volunteers as young as their 20 s12, 
and regional patterns of hypometabolism are not associated with amyloid deposition26. Expression of molecules 
involved in insulin signaling are altered in E4 mouse and human brains27,28. Given the overlap, several anti-diabetic 
agents have been tested for treatment of AD, with many showing reduced benefits in E4 + individuals29. 
However, despite the evidence linking T2D and E4, very few studies have explored the potential interaction of 
these two critical risk factors30,31.
Altered patterns of DNA methylation are present in tissues of individuals with T2D18 and AD32. In particular, 
regulation of 5hmC might modulate hippocampus-dependent cognitive processes. High levels of 5hmC are found 
in the CNS relative to other tissues, particularly in the hippocampus33. In both humans and mice, hippocampal 
function appears to be especially sensitive to the effects of a Western diet34. The exaggerated cognitive impairment 
in E4 HFD mice was hippocampus-dependent, and associated with epigenetic alterations.
DNA methylation and metabolic pathways are highly responsive to environmental cues and each other. For 
instance, the caloric and micro-nutrient composition of the diet influences methylation status, while various met-
abolic pathways are controlled at the epigenetic level21. However, an analysis at each level independently is likely 
insufficient to fully characterize a complex biological system. Thus, we integrated the two ‘omics platforms to 
reveal several intriguing pathways which were altered by E4 and HFD. Of particular interest due to their relative 
novelty and biological relevance were three interconnected metabolic pathways: purine metabolism, glutamate 
metabolism, and the PPP (Fig. 6).
Although the purine metabolic pathway has been associated with the development of diabetic microvascular 
complications, very little is known about its involvement in AD. Purine metabolism is deregulated during AD 
in a manner that is dependent both on brain region and stage of disease35–37. Observed changes in adenosine in 
E4 HFD mice could be secondary to changes in AMP usage, or may alternatively reflect a vascular response. The 
latter scenario is intriguing given that several purines have vasoreactive properties, and that purine metabolites 
accumulate (and glucose oxidation via the PPP increases) during cerebral hypoxia in mammals38,39. Further, our 
5hmC analyses also pointed to vascular and/or BBB dysfunction as areas potentially affected by E4 and HFD, with 
enrichment in pathways related to focal adhesion, adherens junction, and vascular smooth muscle cell contrac-
tion. E4 has been associated with BBB breakdown in multiple studies40, and because T2D and E4 are key risk fac-
tors for both AD and vascular disease, BBB dysfunction and cerebral hypoxia may represent a shared pathology.
The second major metabolic pathway centers on glutamate, the most abundant excitatory neurotransmitter in 
the CNS. Glutamate plays a vital role in brain energy metabolism, linking glucose utilization to neuronal activity, 
and is produced during the first committed, regulated step in the pathway of de novo purine biosynthesis, thereby 
also coupling the PPP with purine metabolism. Similar to our findings, Dumanis et al. showed that E4 mice have 
decreased levels of glutamate compared to mice with E341. E4 has also been shown to impair glutamate receptor 
function by affecting intracellular trafficking42, and increases in glutamate receptors have been described in E4 
mice41.
The integrated analysis also highlighted a novel potential role for the PPP. Aside from supplying ribose-
5-phosphate for purine nucleotide biosynthesis, the PPP plays a crucial role in maintaining cellular redox through 
regeneration of NADPH. Although the PPP remains largely unexplored in the background of neurodegenerative 
disease, two studies have linked PPP enzymatic activity and oxidative stress to AD43,44. Interestingly, the role of 
the PPP in cerebral glucose metabolism and redox maintenance draws some intriguing parallels to cancer biol-
ogy. Unlike normal tissues, cancer cells rely heavily on aerobic glycolysis, a phenomenon known as the Warburg 
effect45. There is a new appreciation for the substantial link between aerobic glycolysis, redox maintenance and the 
regulation of blood flow in the brain. In fact, recent work even suggests that, like cancer cells, neurons display an 
DHRs are similarly altered in E4 LFD and E4 HFD → LFD, compared to E4 HFD mice. The boxes show total 
number of DHRs for each comparison (p < 0.05). (n = 4 pools; 2 pools/experimental group, consisting of 5 
individual DNA samples/pool). (I) The majority of pathways differentially hydroxymethylated in E4 LFD 
mice are similarly altered in E4 HFD → LFD mice. (n = 4 pools; 2 pools/experimental group, consisting of 5 
individual DNA samples/pool). (J-K) The E4 HFD metabolome is significantly altered by a dietary intervention. 
Hierarchical clustering of the top 25 most significantly altered metabolites between E4 HFD and E4 
HFD → LFD mice (J). Pathway impact analysis (K). (n = 5–9). (L) Multiple metabolites are significantly altered 
following the dietary intervention (p < 0.05, t-test). Box and whisker plots reflect metabolite concentrations 
relative to E3 LFD. (n = 5–9). (M) An integrated pathway analysis shows that the dietary intervention affects, 
among others, the three pathways highlighted in Figure 5 (purine metabolism, glutamate metabolism, and 
PPP). *p < 0.05, **p < 0.01 compared to E4 HFD (C,E, ANOVA followed by Tukey’s multiple comparison test; 
B,D,F,G, repeated measures ANOVA). For E, *p < 0.05, compared to Familiar Object (ANOVA followed by 
Tukey’s multiple comparison test). T, target; R, right; L, left; O, opposite. Error bars represent mean ± SEM. E4 
HFD data is reproduced from Figures 1–5.
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adaptive advantage for survival by managing their redox state via the PPP46. Further, the areas of the normal brain 
that demonstrate the highest rates of aerobic glycolysis show near complete overlap with areas of the AD brain 
that preferentially accumulate amyloid, and it has thus been suggested that impairments in aerobic glycolysis may 
contribute to AD pathophysiology47.
Importantly, several of the metabolic pathways we identified as being altered by E4 and HFD have also been 
identified in the brain tissue of AD patients compared to controls, including amino sugar and nucleotide sugar 
metabolism, galactose metabolism, fructose and mannose metabolism, and the PPP48. Notably, these pathways 
represent secondary (non-glucose) sources of energy for neurons. In addition to the cerebral glucose hypome-
tabolism in E4 + individuals, a global metabolic shift toward increased lipid oxidation – at the expense of glucose 
metabolism – was recently described in E4 mice49. Thus, perhaps an inherent inability of E4 + individuals to use 
glucose is reflected in the sum of these findings; although whether it occurs at the level of the BBB or cellular 
uptake, oxidative phosphorylation, aerobic glycolysis or elsewhere remains unclear. Adding further predictive 
value, the only metabolic pathway significantly altered in MCI patients who progressed to AD vs those who did 
not, was the PPP44. Thus, the PPP may represent a novel target which potentially ties E4 to pathological changes 
in glucose metabolism, oxidative stress and neuronal survival.
Finally, because E4 HFD mice were most affected cognitively and demonstrated the most robust 5hmC and 
metabolite changes, we investigated whether these alterations were responsive to beneficial changes in diet as 
previously shown in WT mice22. Many of the genomic regions and pathways that were significantly hypermethyl-
ated in E4 HFD mice were hypomethylated following the HFD → LFD intervention, suggesting that these genes 
may play a role in the functional impairments, and subsequent recovery. Similarly, a number of metabolites and 
pathways altered by HFD were also revealed during an untargeted metabolomics screen of HFD → LFD mice. 
Importantly, the three metabolic pathways most impacted by the intervention were purine metabolism, glutamate 
metabolism, and the PPP. These results point to a functional role for the aforementioned pathways, as they are 
significantly altered by both the chronic HFD and the dietary intervention.
Our results have several important implications: 1) the metabolic and cognitive dysfunction brought on by a 
HFD is magnified by E4, 2) is characterized by a distinct hippocampal epigenome and metabolome, 3) is respon-
sive to a dietary intervention, and 4) may be driven by alterations in metabolic pathways of purine metabolism, 
glutamate, and the PPP. Together, these results suggest a susceptibility of E4+ carriers to metabolic and cognitive 
impairments brought on by a HFD, and may help guide development of novel therapeutic targets for AD and 
related dementias.
Figure 6. Integrated epigenome-metabolome analysis revealed roles for purine metabolism, the pentose 
phosphate pathway, and glutamine and glutamate. For details, see text.
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Methods
Experimental Animals, Biochemical Measures, and Cognitive Analyses. Female homozygous 
human E3 and E4 targeted replacement mice50 were fed a HFD (60% kcal from fat, Research Diets D12492) or 
ingredient-matched LFD (10% kcal from fat, D12450B) for 6 months, beginning at 9 months of age (tested at 
15 months of age). T1D was induced by five days of sequential intraperitoneal injections of low-dose streptozo-
tocin (STZ), beginning at 12 months of age (0.05 mg/g body wt in 0.05 mol/L citrate buffer, pH 4.5). T1D mice 
were tested 3 months after injection of STZ (tested at 15 months of age). Fasting plasma insulin (Millipore) was 
measured after a four hour fast. Glucose tolerance and glucose uptake were performed as described22. Object 
recognition task, spatial learning and memory in the water maze, and cued fear conditioning were assessed as 
described22. Procedures complied with the NIH Guide for the Care and Use of Laboratory Animals and with 
IACUC approval at OHSU.
Untargeted Metabolomics. Hippocampi were dissected and homogenized in RIPA (500 μ l). Metabolites 
were extracted from 100 μ l of hippocampal homogenate and untargeted metabolomics was completed as 
described22,51. Metabolomics data was processed using MarkerView and Peakview software (AB SCIEX) and 
Metaboanalyst52. Metabolite identification was based on mass error (< 30 ppm) and MS/MS fragment ions. Many 
metabolites were further confirmed using retention time and comparison to authentic standards ( ± 1 min) from 
an in-house library (IROA Technologies). LipidMaps, METLIN and HMDB databases were used for MS and 
MS/MS matching. Metaboanalyst heatmap and pathway analyses were performed as described22. For integrated 
pathway analyses, the parameters were set to ‘global test’ and ‘relative betweenness centrality’.
DNA Hydroxymethylation Sequencing and Bioinformatics. DNA was isolated from 200 μ l hip-
pocampal homogenates (described above) and specific antibodies against 5-hydroxymethylcytosine (5hmC) 
were used to immunoprecipitate DNA preparations for hydroxymethyl-DNA immunoprecipitation (hMeDIP) 
as previously described20. Equal concentrations of individual hippocampal DNA samples were pooled to 
form 10 pools for hMeDIP analysis (2 pools/experimental group, consisting of 4–6 individual DNA samples/
pool). Antibodies were used to precipitate genomic regions that are enriched for 5hmC, and following immu-
noprecipitation, high throughput genomic sequencing (Seq) was used to identify these enriched genomic 
regions. Immunoprecipitation, DNA isolation/preparation, and DIP-Seq library preparation were performed 
as described20. Libraries were sequenced on the NextSeq 2500 platform (OHSU Massively Parallel Sequencing 
Shared Resource). For hMeDIP-Seq analyses, 50 bp single read sequence data were mapped to the mouse ref-
erence genome (UCSC mm9) using the Bowtie algorithm using standard flags and allowing two mismatches. 
Sequences that map to a single location were selected and domains enriched for 5hmC were selected using a 
parameter-optimized Monte-Carlo-based segmentation algorithm, as previously described20. A 1,000 base pair 
sliding-window was selected based on iterative analyses that maximized the number of enriched regions. For 
statistical comparisons of hMeDIP biological samples, regions of methylation enrichment were merged and dif-
ferences in methylation interrogated with FDR-adjusted chi-square statistics, as previously described20. hMeDIP 
DIP analyses were validated by replicating hmC DIP in a subset of samples and 5hmC enrichment was assessed 
using real-time PCR primers that target the DIP-Seq centroid of 5 gene-associated regions selected in an unbiased 
manner (Figure S6). Distribution of hMeDIP within various genomic regions and repetitive elements was ana-
lyzed using Fisher’s exact test. For statistical comparisons of hMeDIP biological samples, regions of methylation 
enrichment were merged and differences interrogated with FDR-adjusted chi-square statistics. Distribution of 
5hmC within various genomic regions was analyzed using Fisher’s exact test. GO analyses involved the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. Functionally related terms that shared > 
75% of genes were considered redundant and removed.
Statistical Analyses. All data are expressed as mean ± standard error. Multiple groups and/or multiple time 
points were analyzed using ANOVAs (Graph Pad Prism), or repeated measures ANOVA (time × groups) (SPSS). 
Statistical significance was determined using an error probability level of p < 0.05 corrected by a false discovery 
rate (FDR) analysis (Benjamini Hochberg method).
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